FDA Suggests Revising Cannabis Classification for Medical Use
According to a report by the media outlet Ismorbo on January 22, the U.S. Food and Drug Administration (FDA) recently revealed that cannabis is considered to have legitimate medical uses and has proposed reclassifying it from a Schedule I substance to a Schedule III substance. This decision has sparked widespread attention and discussion.
The FDA has stated that compared to other substances classified as Schedule I or II drugs, marijuana poses a lower threat to public health. While some individuals may face risks due to excessive use of marijuana, the majority of marijuana users do not pose significant risks to themselves or others.
When assessing the risks and benefits of marijuana, the FDA has chosen to use alcohol as a reference standard, despite alcohol not being classified as a controlled substance. The agency acknowledges that there is scientific evidence supporting the use of medical marijuana in treating various symptoms, including but not limited to appetite loss, anxiety disorders, epilepsy, inflammatory bowel diseases, nausea and vomiting, pain, and post-traumatic stress disorder. However, the FDA emphasizes that this does not mean that the safety and effectiveness of marijuana have been fully established.
This proposal could provide more operational freedom for cannabis companies and alleviate tax restrictions dating back 40 years. However, the decision does not explicitly endorse the use of marijuana for treating specific health conditions. This reclassification could also stimulate further research on cannabis, opening up new possibilities for the future development of this field. The long-term impact of this decision on the cannabis industry and related sectors is being closely watched.
Disclaimer:
This article is translated from an original Chinese article available on 2firsts.cn by AI, and has been reviewed and edited by 2FIRSTS's English editorial team. The Chinese original text is the only authoritative source of information. The exclusive copyright and license rights to this article are held by 2FIRSTS Technology Co., Ltd. Any reproduction, reprinting, or redistribution of this article, either in part or in full, requires express written permission from 2FIRSTS and must include clear attribution along with a link to this content. Non-compliance may result in legal action. 2FIRSTS Technology Co., Ltd. reserves the right to pursue legal actions in case of unauthorized use or distribution.